7 stories mentioning HKG:6821Updated 29d ago
Every FINWIRES story that references HKG:6821, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
CIG Shanghai (SHA:603083, HKG:6821) recommended a cash dividend of 0.09 yuan per A share for the first half, according to a Shanghai bourse filing on Tuesday.The company, which manufactures telecommunications, data communications and customer-premises equipment, will pay out a total of 33.1 million yuan in dividends for the first half, inclusive of tax.
CIG Shanghai (SHA:603083, HKG:6821) reported an attributable net profit of 327.7 million yuan for the first half of 2026, up 171% from 121 million yuan a year earlier.Earnings per share rose to 0.93 yuan from 0.45 yuan, according to a Monday filing with the Hong Kong Exchange.Revenue increased 33% year over year to 2.71 billion yuan from 2.04 billion yuan, the communication equipment manufacturer said.
Asymchem Laboratories (HKG:6821, SHE:002821) reported 520.5 million yuan in net profit attributable to shareholders for the first half, down 16% from 617.5 million yuan a year earlier.Earnings per share stood at 1.45 yuan, compared with 1.68 yuan in the year-ago period, according to a Monday filing with the Hong Kong Exchange.Revenue increased 13% year over year to 3.61 billion yuan from 3.19 billion yuan.
Asymchem Laboratories (HKG:6821, SHE:002821) agreed to subscribe for Shanghai Asymchem Biotech Development's newly issued shares for 1.05 billion yuan, according to a Thursday filing on the Hong Kong bourse.The Chinese pharmaceutical company's Shenzhen shares jumped 6%, while Hong Kong shares rose 2% during Friday's morning trade.Asymchem's holdings in Shanghai Asymchem, the company's subsidiary, will rise to 83.5% from 83% after the transaction.Shanghai Asymchem aims to raise its capital to 323.5 million yuan from 228.9 million yuan.Two other investors committed to contribute to Shanghai Asymchem. Individual investors Gao Ling Qirui agreed to commit 177 million yuan, while Hao Hong pledged 12.7 million yuan.
Asymchem Laboratories (Tianjin) (HKG:6821) has an average rating of buy and mean price target of HK$132.96, according to analysts polled by FactSet.
Asymchem Laboratories (HKG:6821, SHE:002821) posted a net profit attributable to shareholders of 304.3 million yuan for the first quarter, down 6.8% from 326.6 million yuan a year earlier, according to a Monday Hong Kong bourse filing.Hong Kong-listed shares of the pharmaceutical outsourcing services firm were up nearly 8% in Tuesday's midday trade.Earnings per share came in at 0.84 yuan, compared with 0.89 yuan in the prior-year period.Revenue rose 17% to 1.80 billion yuan from 1.54 billion yuan a year earlier.
Asymchem Laboratories (HKG:6821, SHE:002821) posted a net profit attributable to shareholders of 1.13 billion yuan for 2025, up 19% from 949.0 million yuan a year earlier, according to a Monday Hong Kong bourse filing.Hong Kong-listed shares of the pharmaceutical outsourcing services firm lost nearly 2% in Tuesday morning trade.Earnings per share came in at 3.16 yuan, compared with 2.69 yuan in the prior year.Revenue rose 15% to 6.67 billion yuan from 5.80 billion yuan in 2024.The board proposed a final dividend of 13 yuan per 10 shares.
